Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

Apr 02, 2020
|
staff reporter

NEW YORK – Amgen and Adaptive Biotechnologies said on Thursday that they are collaborating to discover and develop human antibody-based treatments for COVID-19.

The companies have signed a memorandum of understanding and plan to execute a collaboration and license agreement, the terms of which will not be disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Lots of Voided Tests

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Score Disparities Found

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

Maybe an RNA-DNA World

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

Nature Papers Describe Sequencing of Sperm Genomes, Approach to Detect Residual Cancer, More

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

What's Popular?

In Business News

  1. Twist Bioscience Prices $100M Stock Offering

  2. Igenomix, Ferring Pharmaceuticals Collaborate to Study Infertility, Pregnancy Conditions

  3. FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

  4. Prescient Metabiomics, Harvard Partner on Colon Cancer Biomarker Research

  5. Guardant Health Prices $315M Public Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.